Product Pathways
Products
BCP0109 Roscovitine
Roscovitine is a potent and selective inhibitor of cyclin-dependent kinases (CDK).
BCP0231 JNJ7706621
JNJ-7706621 is a novel cell cycle inhibitor that showed potentv inhibition of several cyclin-dependent kinases (CDK) and Aurora kinases.
BCP0092 PD0332991
PD-0332991 is an orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity.
BCP0193 PHA848125
PHA-848125,a novel cyclin-dependent kinase inhibitor under Phase I/II clinical investigation.
BCP0237 AT-7519(HCI)
AT7519 is a novel multi-CDK inhibitor for CDK1/cyclin B, CDK2/Cyclin A, CDK3/Cyclin E, CDK4/Cyclin D1, CDK5/p35 and CDK6/Cyclin D3.
BCP0238 SNS-032(BMS387032)
SNS-032 (formerly BMS-387032) is a small-molecule cyclin-dependent kinase (CDK) inhibitor currently in phase I clinical trials for the treatment of B-cell malignancies and advanced solid tumors.
BCP0344 PHA-793887
PHA-793887 is a novel and potent inhibitor of CDK2, CDK5 and CDK7 with IC50 of 8 nM, 5 nM and 10 nM, respectively.
BCP0430 AT 7519 mesylate
AT7519 is a novel multi-CDK inhibitor for CDK1/cyclin B, CDK2/Cyclin A, CDK3/Cyclin E, CDK4/Cyclin D1, CDK5/p35 and CDK6/Cyclin D3 with IC50 of 210 nM, 47 nM, 360 nM, 100 nM, 13 nM and 170 nM, respectively.
BCP0432 RO 3306
ATP-competitive, potent cyclin-dependent kinase (cdk) 1 inhibitor.
BCP0481 AT7519
AT7519 is a novel small molecule multi-cyclin-dependent kinase inhibitor.
第一页 1 2 3 最后页 
 
Only for research purpose , not for human consumption Copyright©2012 ShangHai Biochempartner Co.,Ltd.